Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin L Hay

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Drug Discovery Today|September 11, 2020
Streamlined approval of biosimilars: moving on from the confirmatory efficacy trialMarie-Christine Bielsky, Anne Cook, Andrea Wallington, et al.
Experimental Brain Research|May 5, 2016
Responsiveness of electrical nociceptive detection thresholds to capsaicin (8 %)-induced changes in nociceptive processingRobert J Doll, Guido van Amerongen, Justin L Hay, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 2, 2014
Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramineHans G Cruz, Justin L Hay, Petra Hoever, et al.
British Journal of Clinical Pharmacology|March 27, 2016
Pharmacokinetics and pharmacodynamics of multiple doses of BG00010, a neurotrophic factor with anti-hyperalgesic effects, in patients with sciaticaPieter Okkerse, Justin L Hay, Eve Versage, et al.
British Journal of Clinical Pharmacology|June 9, 2016
Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjectsRicardo Alvarez-Jimenez, Geert Jan Groeneveld, Joop M A van Gerven, et al.
British Journal of Clinical Pharmacology|November 28, 2017
Demonstration of an anti-hyperalgesic effect of a novel pan-Trk inhibitor PF-06273340 in a battery of human evoked pain modelsPeter Loudon, Pieter Siebenga, Donal Gorman, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 5, 2012
Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humansMatthias Hoch, Justin L Hay, Petra Hoever, et al.
European Journal of Pain (London, England)|February 23, 2019
Reproducibility of a battery of human evoked pain models to detect pharmacological effects of analgesic drugsPieter S Siebenga, Guido van Amerongen, Pieter Okkerse, et al.
British Journal of Anaesthesia|March 28, 2019
Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABA<sub>A</sub> partial agonist, in humansGuido van Amerongen, Pieter S Siebenga, Rachel Gurrell, et al.
British Journal of Clinical Pharmacology|October 17, 2012
Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteersErik T te Beek, Justin L Hay, Jonathan N Bullman, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Drug Discovery Today|September 11, 2020
Streamlined approval of biosimilars: moving on from the confirmatory efficacy trialMarie-Christine Bielsky, Anne Cook, Andrea Wallington, et al.
Experimental Brain Research|May 5, 2016
Responsiveness of electrical nociceptive detection thresholds to capsaicin (8 %)-induced changes in nociceptive processingRobert J Doll, Guido van Amerongen, Justin L Hay, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 2, 2014
Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramineHans G Cruz, Justin L Hay, Petra Hoever, et al.
British Journal of Clinical Pharmacology|March 27, 2016
Pharmacokinetics and pharmacodynamics of multiple doses of BG00010, a neurotrophic factor with anti-hyperalgesic effects, in patients with sciaticaPieter Okkerse, Justin L Hay, Eve Versage, et al.
British Journal of Clinical Pharmacology|June 9, 2016
Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjectsRicardo Alvarez-Jimenez, Geert Jan Groeneveld, Joop M A van Gerven, et al.
British Journal of Clinical Pharmacology|November 28, 2017
Demonstration of an anti-hyperalgesic effect of a novel pan-Trk inhibitor PF-06273340 in a battery of human evoked pain modelsPeter Loudon, Pieter Siebenga, Donal Gorman, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 5, 2012
Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humansMatthias Hoch, Justin L Hay, Petra Hoever, et al.
European Journal of Pain (London, England)|February 23, 2019
Reproducibility of a battery of human evoked pain models to detect pharmacological effects of analgesic drugsPieter S Siebenga, Guido van Amerongen, Pieter Okkerse, et al.
British Journal of Anaesthesia|March 28, 2019
Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABA<sub>A</sub> partial agonist, in humansGuido van Amerongen, Pieter S Siebenga, Rachel Gurrell, et al.
British Journal of Clinical Pharmacology|October 17, 2012
Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteersErik T te Beek, Justin L Hay, Jonathan N Bullman, et al.
Pageof 3